Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth ...
INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...
1h
Everyday Health on MSNRFK Jr. Asks Food Companies to Stop Using Artificial DyesThe U.S. Health and Human Services Secretary is pushing to end a rule that allows food companies to use additives that ...
Investing.com -- The U.S. Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) unveiled a series of actions and programs on Tuesday, aimed at improving the quality, ...
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
Brandon Gill and five other House Republicans filed impeachment articles against Judge James Boasberg. Only 15 federal judges ...
4h
Zacks Investment Research on MSNBayer's sNDA for Kerendia Label Expansion Gets FDA's Priority ReviewBayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.
Despite the Trump administration's shake-up of the agency, the US FDA is the first port of call for most ASX biotechs.
One practice now under greater scrutiny is health care insurers’ use of artificial intelligence (AI) algorithms to deny ...
Proposals to eliminate the self-affirmed GRAS pathway have sent shockwaves through the food industry. But what do they mean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results